Trajectories of Adherence to Biologics in Patients With Inflammatory Bowel Diseases: A Large‐Scale Multi‐Regional Italian Study Through the VALORE Distributed Database
Pharmacoepidemiology and Drug Safety · 2025-10 · 34 (10)
DOI: 10.1002/pds.70230 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 09.10.2025. Verfasst von Sabrina Giometto und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Biological Products, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute.
Abstract (Originalsprache)
This study aimed to identify and describe trajectories of adherence to biologics in patients with IBDs and to identify adherence determinants in the Italian real‐world setting. We conducted a retrospective cohort study across 12 Italian regions, including new users of biologics with inflammatory bowel diseases (IBDs), between 2010 and 2019 and followed them for 3 years. We assessed adherence longitudinally, and we identified trajectories using nonparametric methods. To identify determinants of adherence, we used multinomial multivariate regression models. We included 20 150 subjects in the final cohort, mostly male (56%), < 65 years old (92%), and with Crohn's disease (58%). We identified three trajectories of adherence to biologics for IBDs: one group (19% of the cohort) maintained high adherence throughout the observation period, while the largest group (46%) initially reduced adherence, stabilizing around 70%. The remaining group (35%) gradually decreased adherence over the entire follow‐up, reaching 20%. Being female (odds ratio (OR) 1.52, 95% confidence interval (CI) 1.40–1.65), older (OR 1.44, 95% CI 1.21–1.70), and having adalimumab as index drug were each positively associated with low adherence compared to high adherence. In contrast, starting treatment with a biosimilar (OR 0.47, 95% CI 0.42–0.52) was negatively associated with low adherence. Our findings highlight that one in three patients with IBDs gradually reduced adherence to biologics within the first 3 years of treatment. Differences were observed according to the initial biologic dispensed and patient characteristics such as sex and age, with females and older patients positively associated with low adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
- Lombardy Regional Epidemiologic Observatory, Milan, Italy.
- Azienda Regionale per l'Innovazione e gli Acquisti, S.p.A, Milan, Italy.
- Centro Regionale Farmacovigilanza Regione Puglia, Bari, Italy.
- Azienda Zero, Regione Veneto, Padova, Italy.
ORCID-Profile: Valeria Belleudi, Marco Tuccori, Rosa Gini
Förderung
- Agenzia Italiana del Farmaco, Ministero della Salute
Zitieren
APA
Giometto, S., Spini, A., Pellegrini, G., Ingrasciotta, Y., Bellitto, C., Soardo, F., L'Abbate, L., Leoni, O., Mazzone, A., Ancona, D., Stella, P., Cavazzana, A., Scapin, A., Lopes, S., Belleudi, V., Ledda, S., Carta, P., Rossi, P., Ejlli, L., …, & Lucenteforte, E. (2025). Trajectories of Adherence to Biologics in Patients With Inflammatory Bowel Diseases: A Large‐Scale Multi‐Regional Italian Study Through the VALORE Distributed Database. Pharmacoepidemiology and Drug Safety, 34(10). https://doi.org/10.1002/pds.70230
Vancouver
Giometto S, Spini A, Pellegrini G, Ingrasciotta Y, Bellitto C, Soardo F, et al. Trajectories of Adherence to Biologics in Patients With Inflammatory Bowel Diseases: A Large‐Scale Multi‐Regional Italian Study Through the VALORE Distributed Database. Pharmacoepidemiology and Drug Safety. 2025;34(10). doi:10.1002/pds.70230
BibTeX
@article{Giometto2025,
author = {Giometto, Sabrina and Spini, Andrea and Pellegrini, Giorgia and Ingrasciotta, Ylenia and Bellitto, Chiara and Soardo, Federica and L'Abbate, Luca and Leoni, Olivia and Mazzone, Arianna and Ancona, Domenica and Stella, Paolo and Cavazzana, Anna and Scapin, Angela and Lopes, Sara and Belleudi, Valeria and Ledda, Stefano and Carta, Paolo and Rossi, Paola and Ejlli, Lucian and Sapigni, Ester and Puccini, Aurora and Allotta, Alessandra and Pollina, Sebastiano Addario and Da Cas, Roberto and Bucaneve, Giampaolo and Mangano, Antea Maria Pia and Balducci, Francesco and Sorrentino, Carla and Senesi, Ilenia and Tuccori, Marco and Gini, Rosa and Spila Alegiani, Stefania and Massari, Marco and Trifirò, Gianluca and Lucenteforte, Ersilia},
title = {Trajectories of Adherence to Biologics in Patients With Inflammatory Bowel Diseases: A Large‐Scale Multi‐Regional Italian Study Through the VALORE Distributed Database},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
volume = {34},
number = {10},
doi = {10.1002/pds.70230}
}
EUVIMED